Science Spotlight: About GlycoConnect® . GlycoConnect® replaces the existing antibody glycan with a therapeutic payload, enabling site specific bioconjugates without antibody engineering. For more information:

Next week between 19-21 August, members of the @Synaffix team will be in Boston for the 3rd Annual ADC Linker & Conjugation Summit. Reach out to learn more about our cutting-edge, clinical-stage ADC platform technology. #antibodydrugconjugates #ADCs #drugdevelopment #biotech

Science Spotlight: @Synaffix's Consolidated Technology Platform for Proprietary Best-in-Class ADCs. Protected by over 30 patent families, our clinical stage platform technology consists of three integral components. For more information:

#antibodydrugconjugates #oncology #newfacility #ADCs #drugdevelopment #biotech.

2025 has seen @Synaffix go from strength to strength, as we continue to lead from the front as the industry's partner of choice for ADCs!. Join us as we reflect on the year so far and stay tuned for further updates as we carry this momentum into the second half of 2025!

📢 ICYMI - back in March, the @Synaffix team celebrated a major milestone as we launched our new facility in Oss with a spectacular ribbon cutting ceremony and Amsterdam canal cruise!. Watch the montage below for some snippets of the event!

Members of the @Synaffix team will be in Boston from June 16-19, 2025 for this year's @Biotechnology Innovation Organization (BIO) International Convention. Reach out to connect with our team and set up a meeting!. #BIO2025 #ADCs #drugdevelopment #biotech

Catch Anette Sommer, Head of Biochemistry and Lianne Lelieveldt, Senior Scientist at in Basel this week for Antibody Engineering & Therapeutics Europe!. Anette will be speaking and the team will be presenting a poster. #biotech #antibody #drugdiscovery #drugdevelopment #ADCs

The @Synaffix team will be in Incheon, South Korea from June 10-12, 2025 for World ADC Asia 2025. As a Senior Partner of the event, Synaffix is proud to support this conference as it highlights the growing status of Asia in ADC innovation and breakthroughs. #ADCs #biotech

Join @Synaffix on June 1, 2025 in showing support for this year's National Cancer Survivors Day. This important initiative is a celebration of those who have survived, offering inspiration, hope, and support for those recently diagnosed and their families. #oncology #cancer

The Synaffix team had a fantastic time in Chicago recently for #AACR2025. The event was filled with contributions from leading innovators in the #oncology space. Members of the Synaffix team presented two posters which you can view here:

Catch Synaffix in Chicago for the American Association for Cancer Research (AACR) Annual Meeting 2025, held between April 25-30, 2025!. The Synaffix team are delivering two presentations, and the posters are available to view here:

Last week Synaffix had the pleasure of hosting a ribbon cutting ceremony to unveil our brand new cutting-edge facility in Oss!. With this new facility comes increased and streamlined research capabilities, bolstering our offering as the industry's ADC partner of choice. #ADCs

Tomorrow marks #IWD2025, and at @Synaffix we are proud to support such an important initiative. Join us on this day as we #AccelerateAction and strive for a world that is diverse, equitable, and inclusive.

Catch @Synaffix Head of R&D Floris van Delft along with other members of the team in London next week for the 15th Annual #WorldADC 3rd- 6th March 2025. Get in touch to arrange a meeting. We hope to see you there!. #WorldADC #ADCs #bispecifics

Today marks #WorldCancerDay, which @Synaffix is proud to support. At #Synaffix it is our mission to use our innovative #ADC technology platform to aid the development of best-in-class targeted cancer therapies. #adcs #oncology #UnitedbyUnique

Read more:

Read more:

@Synaffix today announces it has signed a licensing deal with Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of @mcgc_en. The agreement grants MTPC access to Synaffix's technology platform for the development of a single #ADC program. Full press release below.

@Synaffix today announces it has entered into an exclusive #ADC license agreement with @Boehringer worth over $1.3 billion. The agreement grants BI access to Synaffix's technology platform for an agreed but undisclosed number of targets. Full press release below.